Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard: Amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery

Antonella Poloni, Pietro Leoni, Laura Curzi, Isabella Cantori, Stefania Mancini, Mauro Montanari, Maria Cristiana Masia, Attilio Olivieri

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Ex vivo pharmacological purging of bone marrow has been used to eliminate clonogenic tumor cells contaminating the autograft and potentially responsible of relapse. A considerable improvement of pharmacological purging would be achieved only if normal marrow progenitor cells could be selectively protected by the cytotoxicity of these agents. Amifostine (WR-2721; Ethyol), a phosphorylated aminothiol compound, has been shown to have this property both in vivo and in vitro. We describe here, an experimental model for ex vivo purging of peripheral blood progenitor cell (PBPC) collections based on the combination of 3 mg/ml of amifostine and the alkylating agent nitrogen mustard. Amifostine pretreatment resulted in a statistically significant protection of normal late and early progenitor cells. Under the same experimental conditions, we observed a 4-6 log reduction of contaminating leukemic cells (i.e., K-562 and CEM) and in contrast to the protection of normal peripheral blood progenitor cells, preincubation of contaminating K- 562 or CEM with amifostine did not significantly alter the LD95 nitrogen mustard concentration. Moreover, when we tested fresh human leukemia progenitor cells, amifostine pretreatment sensitized the leukemic cells to the cytotoxic effects of NM.

Original languageEnglish
Pages (from-to)1548-1556
Number of pages9
JournalExperimental Hematology
Volume27
Issue number10
DOIs
Publication statusPublished - Oct 1999

Fingerprint

Amifostine
Leukapheresis
Mechlorethamine
Blood Cells
Stem Cells
Pharmacology
Bone Marrow Purging
Alkylating Agents
Autografts
Leukemia
Theoretical Models
Bone Marrow
Recurrence

Keywords

  • Amifostine
  • Nitrogen Mustard
  • PBPC
  • Purging

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard : Amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery. / Poloni, Antonella; Leoni, Pietro; Curzi, Laura; Cantori, Isabella; Mancini, Stefania; Montanari, Mauro; Masia, Maria Cristiana; Olivieri, Attilio.

In: Experimental Hematology, Vol. 27, No. 10, 10.1999, p. 1548-1556.

Research output: Contribution to journalArticle

Poloni, Antonella ; Leoni, Pietro ; Curzi, Laura ; Cantori, Isabella ; Mancini, Stefania ; Montanari, Mauro ; Masia, Maria Cristiana ; Olivieri, Attilio. / Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard : Amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery. In: Experimental Hematology. 1999 ; Vol. 27, No. 10. pp. 1548-1556.
@article{bdd8700b3eef41a1ba9b32a183d5bc84,
title = "Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard: Amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery",
abstract = "Ex vivo pharmacological purging of bone marrow has been used to eliminate clonogenic tumor cells contaminating the autograft and potentially responsible of relapse. A considerable improvement of pharmacological purging would be achieved only if normal marrow progenitor cells could be selectively protected by the cytotoxicity of these agents. Amifostine (WR-2721; Ethyol), a phosphorylated aminothiol compound, has been shown to have this property both in vivo and in vitro. We describe here, an experimental model for ex vivo purging of peripheral blood progenitor cell (PBPC) collections based on the combination of 3 mg/ml of amifostine and the alkylating agent nitrogen mustard. Amifostine pretreatment resulted in a statistically significant protection of normal late and early progenitor cells. Under the same experimental conditions, we observed a 4-6 log reduction of contaminating leukemic cells (i.e., K-562 and CEM) and in contrast to the protection of normal peripheral blood progenitor cells, preincubation of contaminating K- 562 or CEM with amifostine did not significantly alter the LD95 nitrogen mustard concentration. Moreover, when we tested fresh human leukemia progenitor cells, amifostine pretreatment sensitized the leukemic cells to the cytotoxic effects of NM.",
keywords = "Amifostine, Nitrogen Mustard, PBPC, Purging",
author = "Antonella Poloni and Pietro Leoni and Laura Curzi and Isabella Cantori and Stefania Mancini and Mauro Montanari and Masia, {Maria Cristiana} and Attilio Olivieri",
year = "1999",
month = "10",
doi = "10.1016/S0301-472X(99)00086-7",
language = "English",
volume = "27",
pages = "1548--1556",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "10",

}

TY - JOUR

T1 - Ex vivo pharmacological purging of leukapheresis collections with nitrogen mustard

T2 - Amifostine pretreatment improves both early and late peripheral blood progenitor cell recovery

AU - Poloni, Antonella

AU - Leoni, Pietro

AU - Curzi, Laura

AU - Cantori, Isabella

AU - Mancini, Stefania

AU - Montanari, Mauro

AU - Masia, Maria Cristiana

AU - Olivieri, Attilio

PY - 1999/10

Y1 - 1999/10

N2 - Ex vivo pharmacological purging of bone marrow has been used to eliminate clonogenic tumor cells contaminating the autograft and potentially responsible of relapse. A considerable improvement of pharmacological purging would be achieved only if normal marrow progenitor cells could be selectively protected by the cytotoxicity of these agents. Amifostine (WR-2721; Ethyol), a phosphorylated aminothiol compound, has been shown to have this property both in vivo and in vitro. We describe here, an experimental model for ex vivo purging of peripheral blood progenitor cell (PBPC) collections based on the combination of 3 mg/ml of amifostine and the alkylating agent nitrogen mustard. Amifostine pretreatment resulted in a statistically significant protection of normal late and early progenitor cells. Under the same experimental conditions, we observed a 4-6 log reduction of contaminating leukemic cells (i.e., K-562 and CEM) and in contrast to the protection of normal peripheral blood progenitor cells, preincubation of contaminating K- 562 or CEM with amifostine did not significantly alter the LD95 nitrogen mustard concentration. Moreover, when we tested fresh human leukemia progenitor cells, amifostine pretreatment sensitized the leukemic cells to the cytotoxic effects of NM.

AB - Ex vivo pharmacological purging of bone marrow has been used to eliminate clonogenic tumor cells contaminating the autograft and potentially responsible of relapse. A considerable improvement of pharmacological purging would be achieved only if normal marrow progenitor cells could be selectively protected by the cytotoxicity of these agents. Amifostine (WR-2721; Ethyol), a phosphorylated aminothiol compound, has been shown to have this property both in vivo and in vitro. We describe here, an experimental model for ex vivo purging of peripheral blood progenitor cell (PBPC) collections based on the combination of 3 mg/ml of amifostine and the alkylating agent nitrogen mustard. Amifostine pretreatment resulted in a statistically significant protection of normal late and early progenitor cells. Under the same experimental conditions, we observed a 4-6 log reduction of contaminating leukemic cells (i.e., K-562 and CEM) and in contrast to the protection of normal peripheral blood progenitor cells, preincubation of contaminating K- 562 or CEM with amifostine did not significantly alter the LD95 nitrogen mustard concentration. Moreover, when we tested fresh human leukemia progenitor cells, amifostine pretreatment sensitized the leukemic cells to the cytotoxic effects of NM.

KW - Amifostine

KW - Nitrogen Mustard

KW - PBPC

KW - Purging

UR - http://www.scopus.com/inward/record.url?scp=0032872206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032872206&partnerID=8YFLogxK

U2 - 10.1016/S0301-472X(99)00086-7

DO - 10.1016/S0301-472X(99)00086-7

M3 - Article

C2 - 10517497

AN - SCOPUS:0032872206

VL - 27

SP - 1548

EP - 1556

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 10

ER -